Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
FAIL · Does not pass the screen
16.93 USD
At the last full screen 2025-12-31
Screened 2025-12-31 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Theravance Biopharma, Inc. holds its Accumulation at $16.93. Consolidating, no directional conviction, held for 40 days.
As held on the ledger · 2025-12-31
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 40 days
Price at the screen
$16.93
Valuation
7.59 trailing · 21.16 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.17
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
8.79%
Below 33%
Interest-bearing debt is just 8.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
2.29%
Below 33%
Cash held in interest-bearing accounts and securities is 2.3% of assets, under the one-third limit.
Pass
Receivables
43.94%
Below 49%
Money owed to the company is 43.9% of assets, under the 49% limit.
Pass
Revenue purity
9.47%
Below 5%
9.5% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2025-12-31 screen. The gold marker is the market price at the same screen. The price runs 6.1% above the base estimate.
Third-party analyst targets: 3 covering, consensus Hold. The average target sits +0% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2025-12-31 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TBPH trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 53%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it buy, with a mean price target of $17.
2026-07-18Markdown$16.64+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 53%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it buy, with a mean price target of $17.
2026-07-03Markdown$16.64+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$16.64Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.